Monoclonal antibodies as therapeutic agents for cancer

被引：263

作者：

Harris, M ^{[1
]}

机构：

[1] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3050, Australia

来源：

LANCET ONCOLOGY | 2004年 / 5卷 / 05期

关键词：

D O I：

10.1016/S1470-2045(04)01467-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Targeted therapies are the focus of much research in oncology. After the development of imatinib for the treatment of chronic myeloid leukaemia, biological therapies that target tumour-associated antigens give hope for improvement of survival in many cancers. At the American Society of Clinical Oncology (ASCO) conference in 2003, data for the antibodies bevacizumb and cetuximab highlighted promising results in clinical trials, including an improvement in survival for metastatic colorectal cancer. Positive results for other antibodies in various stages of clinical development provide hope that anticancer antibodies will have an effect on clinical oncology practice in the next 10 years.

引用

页码：292 / 302

页数：11

共 81 条

[1]

ABBRUZZESE J, 2001, P AN M AM SOC CLIN, V20, P30

[2]

Ahrens N, 2001, BRIT J HAEMATOL, V114, P244

[3]

REDUCED EXPRESSION OF CD20 ANTIGEN AS A CHARACTERISTIC MARKER FOR CHRONIC LYMPHOCYTIC-LEUKEMIA [J].

ALMASRI, NM ;

DUQUE, RE ;

ITURRASPE, J ;

EVERETT, E ;

BRAYLAN, RC .

AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (04) :259-263

[4]

BASELGA J, 2002, P AN M AM SOC CLIN, V21, P226

[5]

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients [J].

Berney, T ;

Delis, S ;

Kato, T ;

Nishida, S ;

Mittal, NK ;

Madariaga, J ;

Levi, D ;

Nery, NR ;

Cirocco, RE ;

Gelman, B ;

Ruiz, P ;

Tzakis, AG .

TRANSPLANTATION, 2002, 74 (07) :1000-1006

[6]

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].

Bookman, MA ;

Darcy, KM ;

Clarke-Pearson, D ;

Boothby, RA ;

Horowitz, IR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290

[7]

Brugger W, 2000, BLOOD, V96, p482A

[8]

BURNSTEIN H, 2001, J CLIN ONCOL, V19, P2722

[9]

BYRD J, 2001, BLOOD, V98

[10]

Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

← 1 2 3 4 5 6 7 8 9 →